Fantin B, Leclercq R, Arthur M, Duval J, Carbon C
Service de Médecine Interne, Hôpital Bichat, Université Paris VII, France.
Antimicrob Agents Chemother. 1991 Aug;35(8):1570-5. doi: 10.1128/AAC.35.8.1570.
Emergence of vancomycin-resistant strains among enterococci raises a new clinical challenge. Rabbits with aortic endocarditis were infected with Enterococcus faecium BM4172, a clinical strain resistant to low levels of vancomycin (MIC, 16 micrograms/ml) and susceptible to teicoplanin (MIC, 1 micrograms/ml), and against its susceptible variant E. faecium BM4172S obtained in vitro by insertional mutagenesis (MICs, 2 and 0.5 micrograms/ml, respectively). Control animals retained 8 to 10.5 log10 CFU/g of vegetation. We evaluated in this model the efficacy of vancomycin (30 mg/kg of body weight; mean peak and trough serum levels, 27 and 5 micrograms/ml, respectively), teicoplanin (standard dose, 10 mg/kg; mean peak and trough levels, 23 and 9 micrograms/ml, respectively; and high dose, 20 mg/kg; mean peak and trough levels, 63 and 25 micrograms/ml, respectively), gentamicin (6 mg/kg; mean peak and trough levels, 8.6 and less than 0.1 micrograms/ml, respectively), alone or in combination, given every 12 h intramuscularly for 5 days. Teicoplanin standard dose was as active as vancomycin against both strains. Vancomycin was not effective against E. faecium BM4172 but was highly effective against E. faecium BM4172S (7.5 +/- 1.1 log10 CFU/g of vegetation versus 4.9 +/- 1.0 log10 CFU/g of vegetation for vancomycin against E. faecium BM4172 and E. faecium BM4172S, respectively; P = 0.0012). A high dose of teicoplanin was more effective than vancomycin against E. faecium BM4172 (4.4 +/- 1.8 log10 CFU/g of vegetation versus 7.5 +/- 1.1 log10 CFU/g of vegetation for teicoplanin high dose and vancomycin, respectively; P less than 0.05). Against E. faecium BM4172 glycopeptide-gentamicin combinations were the most effective regimens in vitro and in vivo (2.8 +/- 0.7 and 3.5 +/- 1.3 log10 CFU/g of vegetation for vancomycin plus gentamicin and teicoplanin standard dose plus gentamicin, respectively; P < 0.05 versus single-drug regimens). We concluded that high-dose teicoplanin or the combination of a glycopeptide antibiotic plus gentamicin was effective against experimental infection due to E. faecium with low-level resistance to vancomycin.
肠球菌中耐万古霉素菌株的出现带来了新的临床挑战。将患有主动脉心内膜炎的兔子感染屎肠球菌BM4172,这是一种对低水平万古霉素耐药(MIC,16微克/毫升)且对替考拉宁敏感(MIC,1微克/毫升)的临床菌株,以及通过插入诱变在体外获得的其敏感变体屎肠球菌BM4172S(MIC分别为2和0.5微克/毫升)。对照动物的赘生物中每克保留8至10.5 log10 CFU。我们在该模型中评估了万古霉素(30毫克/千克体重;平均峰浓度和谷浓度血清水平分别为27和5微克/毫升)、替考拉宁(标准剂量,10毫克/千克;平均峰浓度和谷浓度水平分别为23和9微克/毫升;高剂量,20毫克/千克;平均峰浓度和谷浓度水平分别为63和25微克/毫升)、庆大霉素(6毫克/千克;平均峰浓度和谷浓度水平分别为8.6和低于0.1微克/毫升)单独或联合使用的疗效,每12小时肌肉注射一次,共5天。替考拉宁标准剂量对两种菌株的活性与万古霉素相当。万古霉素对屎肠球菌BM4172无效,但对屎肠球菌BM4172S高度有效(万古霉素对屎肠球菌BM4172和屎肠球菌BM4172S的每克赘生物中CFU分别为7.5±1.1 log10和4.9±1.0 log10;P = 0.0012)。高剂量替考拉宁对屎肠球菌BM4172比万古霉素更有效(替考拉宁高剂量和万古霉素每克赘生物中CFU分别为4.4±1.8 log10和7.5±1.1 log10;P<0.05)。对于屎肠球菌BM4172,糖肽类抗生素与庆大霉素联合使用在体外和体内都是最有效的治疗方案(万古霉素加庆大霉素和替考拉宁标准剂量加庆大霉素每克赘生物中CFU分别为2.8±0.7和3.5±1.3 log10;与单药治疗方案相比P<0.05)。我们得出结论,高剂量替考拉宁或糖肽类抗生素加庆大霉素的联合使用对由对万古霉素低水平耐药的屎肠球菌引起的实验性感染有效。